Search

Displaying results 1481 - 1490 of 3733 in total
  1. Drug

    Pinaverium

    go.drugbank.com/drugs/DB09090
    ApprovedInvestigational

    Although it is not a currently approved drug by the FDA, pinaverium is available in over 60 countries including Canada.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  2. Drug

    Vimseltinib

    go.drugbank.com/drugs/DB17520
    ApprovedInvestigational

    [L52230] It is highly selective, with a >500-fold selectivity for CSF1R over its nearest off-target kinase. … Vimseltinib is a small molecule kinase inhibitor targeting colony-stimulating factor 1 receptor (CSF1R).

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  3. Drug

    Peginterferon alfa-2a

    go.drugbank.com/drugs/DB00008
    ApprovedInvestigational

    Activation and dimerization of this receptor induces the body's innate antiviral response by activating the janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway.

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  4. Drug

    Celecoxib

    go.drugbank.com/drugs/DB00482
    ApprovedInvestigational

    Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptom...

    Synonyms: p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamideCategories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  5. Drug

    Canfosfamide

    go.drugbank.com/drugs/DB04972
    Investigational

    Canfosfamide is an active agent in chemotherapy-resistant ovarian cancer.

  6. Drug

    Vadadustat

    go.drugbank.com/drugs/DB12255
    ApprovedInvestigational

    [A244165] A relatively new and alternative treatment option for patients with anemia associated with CKD is the use of small molecule inhibitors of hypoxia-inducible factor prolyl-hydroxylase (HIF-PH … [A244165] Vadadustat is an orally administered inhibitor of HIF-PH with a safety and efficacy profile non-inferior to [darbepoetin alfa] for the treatment of anemia in patients with CKD undergoing dialysis

    Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 Enzyme Inducers
  7. Drug

    PF-00217830

    go.drugbank.com/drugs/DB12998
    Investigational

    PF-00217830 has been used in trials studying the treatment of Schizophrenia.

  8. Drug

    PB-722

    go.drugbank.com/drugs/DB18447
    Experimental

    PB-722 is a long-acting glucagon receptor agonist.[L48260]

  9. Drug

    Olodaterol

    go.drugbank.com/drugs/DB09080
    ApprovedInvestigational

    A once-a-day treatment with a LABA has several advantages over short-acting bronchodilators and twice-daily LABAs including improved convenience and compliance and improved airflow over a 24-hour period … Activation of the receptor stimulates an associated G protein which then activates adenylate cyclase, catalyzing the formation of cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA).

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 Substrates
  10. Drug

    PF-03814735

    go.drugbank.com/drugs/DB13059
    Investigational

    PF-03814735 has been used in trials studying the treatment of Solid Tumors.